Publications

• Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products.
  J Transl Med Volume: 23 Page(s): 259
  03/04/2025 Authors: Simon CG; Bozenhardt EH; Celluzzi CM; Dobnik D; Grant ML; Lakshmipathy U; Nebel T; Peltier L; Ratcliffe A; Sherley JL
• Mechanism of action, potency and efficacy: considerations for cell therapies.
  J Transl Med Volume: 22 Page(s): 416
  05/02/2024 Authors: Simon CG; Bozenhardt EH; Celluzzi CM; Dobnik D; Grant ML; Lakshmipathy U; Nebel T; Peltier L; Ratcliffe A; Sherley JL
• MULTI-TUMOR ASSOCIATED ANTIGEN SPECIFIC T CELL (TAA-T) THERAPY TO TREAT PEDIATRIC PATIENTS WITH HIGH-RISK CNS TUMORS: THE REMIND TRIAL
  Volume: 25 Page(s): S33 - S33
  06/01/2023 Authors: Geiger A; Diccocio R; Fortiz M; Grant M; Lang H; Shibli A; Datar A; Reynolds E; Lazarski C; Jensen-Wachspress M
• OUTCOMES OF PEDIATRIC PATIENTS WITH HIGH-RISK CNS TUMORS TREATED WITH MULTI-TUMOR ASSOCIATED ANTIGEN SPECIFIC T CELL (TAA-T) THERAPY: THE REMIND TRIAL
  Volume: 24 Page(s): 85 - 86
  06/01/2022 Authors: Hwang E; Fortiz F; Cruz R; Geiger A; Grant M; Lang H; Shibli A; Burnett S; Lazarski C; Tanna J
• Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.
  Blood Adv Volume: 6 Page(s): 2520 - 2534
  04/26/2022 Authors: Kinoshita H; Cooke KR; Grant M; Stanojevic M; Cruz CR; Keller M; Fortiz MF; Hoq F; Lang H; Barrett AJ
• Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
  Blood Adv Volume: 6 Page(s): 473 - 485
  01/25/2022 Authors: Dave H; Terpilowski M; Mai M; Toner K; Grant M; Stanojevic M; Lazarski C; Shibli A; Bien SA; Maglo P
• Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.
  Front Immunol Volume: 13 Page(s): 999298
  01/01/2022 Authors: Stanojevic M; Grant M; Vesely SK; Knoblach S; Kanakry CG; Nazarian J; Panditharatna E; Panchapakesan K; Gress RE; Holter-Chakrabarty J
• Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors.
  Nat Commun Volume: 12 Page(s): 6689
  11/18/2021 Authors: Rivero-Hinojosa S; Grant M; Panigrahi A; Zhang H; Caisova V; Bollard CM; Rood BR
• Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.
  Cytotherapy Volume: 23 Page(s): 694 - 703
  08/01/2021 Authors: Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee P-H; Lang H; Cruz CRY
• THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS
  Volume: 23 Page(s): 52 - 52
  06/01/2021 Authors: Grant M; Fortiz M; Wang L; Lang H; Datar A; Reynolds E; Terpilowski M; Geiger A; Lazarski C; Tanna J
• Simultaneous Detection of Circulating Tumor Antigens in Acute Leukemia after HSCT
  Volume: 26 Page(s): S123 - S123
  03/01/2020 Authors: Stanojevic M; Grant M; Nazarian J; Knoblach S; Panditharatna E; Panchapakesan K; Gress RE; Chakrabarty JH; Wiliams KM
• T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1.
  Front Immunol Volume: 11 Page(s): 575977
  01/01/2020 Authors: Harris KM; Horn SE; Grant ML; Lang H; Sani G; Jensen-Wachspress MA; Kankate VV; Datar A; Lazarski CA; Bollard CM
• Challenges in IBD Research: Environmental Triggers.
  Inflamm Bowel Dis Volume: 25 Page(s): S13 - S23
  05/16/2019 Authors: Ho S-M; Lewis JD; Mayer EA; Plevy SE; Chuang E; Rappaport SM; Croitoru K; Korzenik JR; Krischer J; Hyams JS
• Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders.
  Front Immunol Volume: 10 Page(s): 621
  01/01/2019 Authors: Patel S; Lang H; Sani G; Freeman AF; Leiding J; Hanley PJ; Cruz CR; Grant M; Wang Y; Oshrine B
• Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
  Blood Rev Volume: 32 Page(s): 203 - 224
  05/01/2018 Authors: Grant ML; Bollard CM
• Developing T-cell therapies for lymphoma without receptor engineering.
  Blood Adv Volume: 1 Page(s): 2579 - 2590
  12/12/2017 Authors: Grant M; Bollard CM
• Developing T-cell therapies for lymphoma without receptor engineering.
  Hematology Am Soc Hematol Educ Program Volume: 2017 Page(s): 622 - 631
  12/08/2017 Authors: Grant M; Bollard CM
• Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients After HCT
  Volume: 64 Page(s): S137 - S137
  11/01/2017 Authors: Williams K; Grant M; Ismail M; Hoq F; Manso MM; Hoover J; Mintz E; Namata A; Williams E; Barese C
• Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.
  Clin Transl Immunology Volume: 6 Page(s): e149
  07/01/2017 Authors: Grant ML; Shields N; Neumann S; Kramer K; Bonato A; Jackson C; Baird MA; Young SL
• INFUSION OF DONOR LYMPHOCYTES SPECIFICALLY DIRECTED TO MULTIPLE TUMOR ANTIGENS FOR THE TREATMENT OF HIGH RISK PATIENTS AFTER HCT
  Volume: 19 Page(s): S48 - S48
  05/01/2017 Authors: Williams KM; Grant M; Ismail M; Hoq F; Martin-Manso M; Hoover J; Mintz K; Namata A; Williams E; Barese C
• Infusion of Donor Lymphocytes Specifically Directed to Multiple Tumor Antigens for the Treatment of High Risk Patients after HCT
  Volume: 23 Page(s): S34 - S34
  03/01/2017 Authors: Williams KM; Grant M; Ismail M; Hoq F; Manso MM; Hoover J; Mintz EK; Namata A; Williams E; Barese C
• Baseline findings in the first 60 subjects in pku ascend (016): A double-blind, placebo-controlled, randomized study to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with phenylketonuria (PKU)
  Volume: 105 Page(s): 349 - 349
  03/01/2012 Authors: Prasad S; Burton B; Feigenbaum A; Grant M; Hendren R; Mardach R; Phillips J; Sanchez-Valle A; Singh R; Siriwardena K